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This issue’s Molecular Medicine Select describes recent progress in identifying pathways that dampen in-
flammation in multiple disease contexts including allergic skin reactions, demyelinating diseases, and neuro-
degeneration. In addition to revealing new potential therapeutic targets, these efforts also put a spotlight on
small molecules, including cannabinoids and compounds derived from omega-3 fatty acids, that might be
used to limit the damaging effects of prolonged inflammation.
Cannabinoids Restrain a Rash Response
Allergic contact dermatitis is a common type of rash triggered by, for exam-
ple, jewellery containing nickel. Although mice do not normally develop an
allergic response to nickel-containing ear tags, Karsak et al. (2007) now re-
port observing chronic ear ulcerations in their colony of mice, which had
been bred to lack both CB1 and CB2 cannabinoid receptors (see figure). Ini-
tially the authors investigated whether loss of the CB1 and CB2 receptors
might impair wound healing but found no difference between mice lacking
the two receptors and their wild-type counterparts. They then tested the re-
sponse of these mice to 2,4-dinitrofluorobenzene, a compound that triggers
contact dermatitis, to determine whether the ulcers were due to an allergic
response. They observed a clear difference between the knockout and
wild-type mice that became even more dramatic with repeated exposure
to the compound. Their findings suggest that endogenous cannabinoids,
which are released in allergic inflammation in the skin, act on keratinocytes
or immune cells to reduce the allergic response. Might this discovery lead to
new therapies for allergic contact dermatitis? The authors raise this as a
possibility. The allergic response to 2,4-dinitrofluorobenzene was attenu-
ated by subcutaneous injection or topical application of D9-THC, the
psychoactive compound found in cannabis. Beyond these therapeutic impli-
cations, future work may establish the critical response of target cells that lead to the mitigating effects of
cannabinoids.
M. Karsak et al. (2007). Science 316, 1494–1497.
Protection against Demyelination Is Made aB-crystallin Clear
The small heat-shock protein aB-crystallin is a major autoantigen recognized by T cells in
individuals with multiple sclerosis (MS), a disorder characterized by neuronal demyelin-
ation. According to recent work by Ousman et al. (2007), aB-crystallin protects against
demyelination in experimental autoimmune encephalomyelitis (EAE), a mouse model of
MS induced by immunization with a fragment of myelin oligodendrocyte glycoprotein. It
has been noted that aB-crystallin is massively upregulated in early active MS lesions
and in EAE, although its role in disease progression has been unclear. Now Ousman
and colleagues show that the severity of EAE is greater in mice lacking aB-crystallin, sug-
gesting that its upregulation is a protective response. They observe that the production of
proinflammatory cytokines by both T cells and antigen-presenting cells is higher in
aB-crystallin null mice than in wild-type mice and that caspase-3 cleavage, as evidence
of proapoptotic signaling, is enhanced in astrocytes of mice lacking aB-crystallin (see fig-
ure). These findings suggest that aB-crystallin inhibits both inflammation and glial cell
death in the course of EAE. There is also a strong antibody response to aB-crystallin in
the spinal fluid of MS patients, and this response may limit the protective effect of this pro-
tein. Remarkably, however, intravenous injection of recombinant human aB-crystallin
markedly reduces the severity of EAE in mice, suggesting a new possible therapeutic ap-
proach for the management of MS.
S.S. Ousman et al. (2007). Nature. Published online June 13, 2007. 10.1038/nature05935.
Histamine Receptor Acts as a Gatekeeper in MS Model
The inflammatory mediator histamine has been implicated in both multiple sclerosis (MS) and experimental autoim-
mune encephalomyelitis (EAE), a mouse disease model with a pathophysiology similar to MS. Histamine acts
through one of four G protein-coupled receptors designated H1–H4. Previous efforts have established that the H1
and H2 receptors contribute to EAE by altering cytokine expression and T cell responses. However, it is not clear
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whether the effect of histamine in EAE ismediated solely through these receptors or whether the H3 andH4 receptors
might also contribute. New work by Teuscher et al. (2007) now shows that the course of EAE is accelerated in mice
lacking the H3 receptor, suggesting that its normal role is protective. Interestingly, this occurs even though the pro-
duction of proinflammatory cytokines and T cell activity were not significantly affected by loss of H3 in the early phase
of the disease. Instead, the authors provide evidence that in the absence of H3 receptor signaling there is an increase
in permeability of the blood brain barrier, which likely enhances T cell migration into the central nervous system. H3 is
expressed at presynaptic terminals in the nervous system and regulates neurotransmitter release. Future work will
be necessary to determine the mechanism by which presynaptic histamine receptors induce a change in vascular
permeability in the brain.
C. Teuscher et al. (2007). Proc. Natl. Acad. Sci. USA 104, 10146–10151. Published online June 4, 2007. 10.1073/
pnas.0702291104.
LXR Nuclear Receptors Keep Neuroinflammation in Check
Liver x receptors (LXR) a and b are nuclear receptors that control cholesterol homeo-
stasis and inflammation. Recent work by Zelcer et al. (2007) now report a new potential
role for LXRs in neurodegeneration. They show that that loss of either LXR a or b leads
to an increase in amyloid deposition in a mouse model of Alzheimer’s disease (see fig-
ure). Because previous findings have indicated that LXRs dampen the inflammatory re-
sponses of macrophages, Zelcer et al. examined the role of LXRs in microglia, the
functional counterpart of macrophages in the central nervous system. Of the many
factors that likely contribute to Alzheimer’s disease, one possibility is that chronic
inflammation impairs the phagocytic clearance of amyloid plaques by microglia. The
authors show that the production of inflammatory cytokines by glial cultures (which
contained a mixture of glial cell types including microglia) to Ab peptide was inhibited
by treatment with an LXR agonist and increased when expression of LXRs was absent.
Inflammatory cytokines, such as IL-1b, are known to decrease the phagocytic activity
of microglia, and the authors establish that an LXR agonist can reverse the decrease in
the phagocytic response elicited by IL-1b. Although inflammation is typically consid-
ered a secondary rather than an instigating factor in Alzheimer’s disease, these and
other recent findings suggest that LXR agonists may have the potential to slow the
progression of the disease by stemming the inflammatory response and enhancing
phagocytic clearance of Ab.
N. Zelcer et al. (2007). Proc. Natl. Acad. Sci. USA 104, 10601–10606. Published online June 11, 2007. 10.1073/
pnas.0701096104.
Compounds that Tell Inflammation when the Party Is over
Acute inflammation is resolved when leukocytes brought to the site of tissue
injury go back into circulation or are otherwise cleared by phagocytes.
Schwab et al. now identify two new compounds that direct the traffic and
clearance of leukocytes brought to the site of injury. These compounds, pro-
tectin D1 (PD1) and resolvin E1 (RvE1), are biosynthesized from omega-3
polyunsaturated fatty acids and were first identified in resolving tissue exu-
dates, a fluid containing plasma components and leukocytes that promotes
the resolution of acute inflammation. The authors induced acute inflamma-
tion by intraperitoneal injection of zymosan, a yeast cell wall polysaccharide
that triggers Toll-like receptor signaling. An important step in alleviating in-
flammation is the clearance of inflammatory polymorphonuclear neutrophils
(PMNs) by phagocytic macrophages. They show that PD1 and RvE1 en-
hance the phagocytic activity of macrophages, increasing clearance of ap-
optotic PMNs (see figure). Treatment with RvE1 and PD1 in vivo increased
the amounts of phagocytosed zymosan observed in leukocytes carried
into the lymphatic system. PD1 and RvE1 also decrease leukocyte infiltration when administered at peak inflamma-
tion. Future work into the mechanism of action for these promising compounds might reveal the relevant pathways
that promote the phagocytic clearance of PMNs and that regulate leukocyte trafficking.
J.M. Schwab et al. (2007). Nature 447, 869–874.
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